• Medical Professionals
    • Information for Healthcare Providers
    • Clinical Studies
    • Expanded Access
    • Educational Grants
    • Request Information
  • Press releases
  • Suppliers
  • Contact
  • Skip to main content
  • Skip to footer

Atara Biotherapeutics

  • About
    • Company
    • Management Team
    • Board of Directors
    • Collaborators
    • Contact
  • Technology
  • Pipeline
    • Atara Pipeline
    • Tab-cel
    • ATA188
    • ATA2271/ATA3271
    • ATA3219
  • Patients
    • Mission to Serve Patients
    • Clinical Studies
    • Expanded Access
    • Request Information
    • PTLD Champions
    • Multiple Sclerosis
  • Investors & Media
    • Investors & Media
    • News & Events
    • Financial Results
    • ATRA Stock
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Careers
    • Join Our Team
    • Life at Atara
    • Explore Career Opportunities
    • Tech Ops
    • Job Search
  • Medical Professionals
  • Suppliers
  • Press Releases
  • Contact
  • LinkedIn
  • Twitter
Investors & Media

Investors & Media

  • Investors & Media
  • News & Events
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Email Alerts
    • Investor & Media Contacts
  • Financial Results
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • ATRA Stock
    • Quote
    • Charts
    • Historical Data
    • FAQ
    • Classification Info
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Contact The Board
  • News
  • Careers

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • Events
  • Presentations
  • Email Alerts
  • Investor & Media Contacts

Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors

Apr 30, 2020 8:30am EDT

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Apr 22, 2020 8:30pm EDT

Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic

Apr 02, 2020 8:30am EDT

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial ResultsĀ and Recent Clinical, Operational and Strategic Progress

Feb 27, 2020 7:30am EST

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Feb 21, 2020 4:00pm EST

Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

Feb 20, 2020 4:00pm EST

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020

Feb 19, 2020 4:00pm EST

Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer

Feb 05, 2020 8:30am EST

Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference

Jan 12, 2020 2:00pm EST

Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-celĀ® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting

Dec 09, 2019 10:00am EST
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...23
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed

    Footer

    • LinkedIn linkedin
    • Twitter twitter
    © 2021 Atara Biotherapeutics, Inc. All Rights Reserved
    • Privacy Policy
    • Sitemap

    This website uses cookies and similar technologies to optimise and improve the experience on our site. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy


    OK